Future Directions for Genomic Testing in Early-Stage Breast Cancer

Dr. Allison DiPasquale and Dr. Sonya Reid conclude the discussion by highlighting the future of personalized care in early-stage HR-positive, HER2-negative breast cancer and the evolving role of genomic testing. Dr. Reid emphasizes that integrating genomic assay results with clinicopathologic risk factors has enabled more individualized treatment recommendations while reducing unnecessary therapy for appropriate patients. She also discusses ongoing research aimed at refining treatment strategies, particularly for premenopausal patients with node-positive disease, with the goal of determining whether some patients may safely avoid chemotherapy in the future. Dr. DiPasquale reflects on the continued evolution of breast cancer management, noting that emerging evidence and novel therapeutic approaches will further enhance personalized care while maintaining appropriate treatment intensity. Both faculty underscore the importance of continued clinical research and multidisciplinary collaboration to optimize patient outcomes. The program concludes with key take-home messages reinforcing the value of genomic testing in guiding evidence-based decision-making for patients with early-stage breast cancer.